Comparative Pharmacology
Head-to-head clinical analysis: ANDROID 25 versus TESTODERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID 25 versus TESTODERM.
ANDROID 25 vs TESTODERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.
Testosterone replacement therapy: binds to androgen receptors, activating gene transcription for protein synthesis and muscle growth.
Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.
One to two 2.5 mg or 5 mg patches applied to clean, dry, intact skin of the back, abdomen, upper arms, or thighs once daily (approximately every 24 hours).
None Documented
None Documented
Terminal elimination half-life: 10–100 minutes (testosterone); clinical context: rapid clearance necessitates frequent dosing or use of esters for sustained effect
Terminal elimination half-life is approximately 10-100 minutes for free testosterone in plasma; for total testosterone (including bound), the apparent half-life ranges from 2-4 hours after transdermal application, with significant interindividual variability.
Renal: 90% (as glucuronide and sulfate conjugates, 5–10% unchanged); fecal/biliary: 10%
Primarily renal (approximately 90% as glucuronide and sulfate conjugates, <10% as unchanged testosterone); about 6% is excreted in feces via biliary elimination.
Category C
Category C
Androgen
Androgen